[On the therapeutic combination of S-adenosylmethionine with D-penicillamine in Wilson's disease].
After some general preliminary remarks concerning aetiopathogenetic hypoteses and therapeutic possibilities for Wilson's disease, the Authors report the data obtained from a long-term study carried out on a family of nine brothers. These subjects were all affected with Wilson's syndrome and kept under a D-penicillamine treatment. The addition of 4-5 oral adminstrations a day of 30 mg SAMe resulted in highly significant favourable modifications of all the laboratory data considered to test liver function. The progressive worsening of the same data observed after 60, 90 and 120 days from SAMe withdrawal, seems to prove the actual activity of this molecule on liver function. During SAMe therapy no clinical and laboratory side-effects (macular and papular eruption, pruritus, neutropenia, thrombocytopenia, etc.) were observed while they were detectable in some patients treated with D-penicillamine alone.
D000293:Adolescent; D000328:Adult; D001798:Blood Proteins / Q000032:analysis; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006527:Hepatolenticular Degeneration / Q000188:drug therapy*; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D010396:Penicillamine / Q000627:therapeutic use*; D012436:S-Adenosylmethionine / Q000627:therapeutic use*
D001798:Blood Proteins; D012436:S-Adenosylmethionine; D010396:Penicillamine